Invention Grant
- Patent Title: Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
-
Application No.: US16046332Application Date: 2018-07-26
-
Publication No.: US10233173B2Publication Date: 2019-03-19
- Inventor: Gang Chen , Christa C Chrovian , Heather R. Coate , Curt A. Dvorak , Christine F. Gelin , Afton Hiscox , Michael A. Letavic , Jason C. Rech , Akinola Soyode-Johnson , Brice Stenne , Jessica L. Wall , Wei Zhang
- Applicant: JANSSEN PHARMACEUTICA NV
- Applicant Address: BE Beerse
- Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee Address: BE Beerse
- Agency: Biospark Intellectual Property Law
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D401/14 ; C07D403/12 ; C07D403/14 ; C07D405/14 ; C07D409/14 ; C07D413/12 ; C07D413/14 ; C07D417/12 ; A61K31/4192 ; A61K31/427 ; A61K31/4439 ; A61K31/497 ; A61K31/501 ; A61K31/506 ; A61K31/5377
Abstract:
Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
Public/Granted literature
- US20180334451A1 SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS Public/Granted day:2018-11-22
Information query
